Haemonetics Corporation reported fiscal third‑quarter 2025 results that surpassed analyst expectations, delivering net income of $44.7 million and an adjusted earnings per share of $1.31, a $0.04 or 3.1% beat over the consensus estimate of $1.27. The diluted EPS of $0.95 is also disclosed, but the adjusted figure is the primary metric used by investors to gauge performance.
Revenue for the quarter reached $338.97 million, up 1.4% sequentially and 2.7% year‑over‑year, driven by a 3.5% increase in Plasma segment sales and a flat Hospital segment. The Blood Center segment, however, declined 19.6% due to the divestiture of its Whole Blood product line, offsetting gains in core areas and contributing to the modest revenue growth.
Operating margin expanded to 26.3% from 26.3% a year ago, while adjusted gross margin rose to 60.2% from 57.7%. The margin lift reflects a shift toward higher‑margin products, disciplined cost management, and pricing power in the Plasma and Blood Management Technologies segments, even as the company invested in new product launches and portfolio restructuring.
Management raised its full‑year 2026 guidance, projecting adjusted EPS of $4.90 to $5.00—up from the prior $4.80 to $5.00 range—and boosting free‑cash‑flow guidance to $200 million to $220 million from $170 million to $210 million. CEO Chris Simon said the results “reflect the underlying strength of our core businesses” and that “Blood Management Technologies and Plasma continue to drive our strong performance while we take targeted actions to reestablish momentum in Interventional Technologies and prepare for a U.S. launch of PerQseal Elite.” CFO James D’Arecca highlighted the guidance increase as evidence of confidence in sustained profitability.
Headwinds remain in the Blood Center segment due to the divestiture and softness in Interventional Technologies, but tailwinds from Plasma and Blood Management Technologies, along with margin expansion and improved cash flow, position Haemonetics for continued growth. The company’s strategic focus on high‑margin products and portfolio optimization signals a clear path toward long‑term value creation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.